- Page 1
- Page 2 - Page 3 - Page 4 - Page 5 - Page 6 - Page 7 - Page 8 - Page 9 - Page 10 - Page 11 - Page 12 - Page 13 - Page 14 - Page 15 - Page 16 - Page 17 - Page 18 - Page 19 - Page 20 - Page 21 - Page 22 - Page 23 - Page 24 - Page 25 - Page 26 - Page 27 - Page 28 - Page 29 - Page 30 - Page 31 - Page 32 - Page 33 - Page 34 - Page 35 - Page 36 - Page 37 - Page 38 - Page 39 - Page 40 - Page 41 - Page 42 - Page 43 - Page 44 - Page 45 - Page 46 - Page 47 - Page 48 - Page 49 - Page 50 - Page 51 - Page 52 - Flash version © UniFlip.com |
Ta rg e t ing Par k in s o n’s Dis e as e:
Dr. Mouradian
Secures Two New Patents,
HOPE
M
ore than one million people in the United States suffer from Parkinson’s disease. Worldwide, the total is estimated to be at least seven million. As life spans grow longer, this devastating disease with an average onset age of 60 will increase its toll on patients, families, and
society. The case is clear for developing novel therapies, free of adverse effects, to alleviate symptoms and to slow or halt the otherwise inevitable progression of the disease. “This is my life’s work,” says M. Maral Mouradian, MD, William Dow Lovett Professor of Neurology and director, Center for Neurodegenerative and Neuroimmunologic Diseases. Dr. Mouradian’s research took a large step forward in early 2016, when she secured patents in support of two distinct projects. They will protect her right to develop and commercialize novel forms of therapy for patients with Parkinson’s disease.
B y K a t e O ’ N e i l l • Photos by Steve Hockstein
Research and
Promoting
Robert Wood Johnson I MEDICINE 9
|